AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Argent BioPharma Limited

0.057

0.000

Volume:11.24K

Turnover:641.00

Market Cap:4.96M

PE:-0.18

High:0.057

Open:0.057

Low:0.057

Close:0.057

52wk High:0.320

52wk Low:0.052

Shares:86.94M

Float Shares:27.70M

Volume Ratio:0.35

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.312

EPS(LYR):-0.312

ROE:--

ROA:-147.52%

PB:-0.57

PE(LYR):-0.18

Loading ...

Overview Company News Filings

Argent Biopharma Ltd-Streamlined Acquisition of Auscann Assets

THOMSON REUTERS

Argent Biopharma Ltd - to Buy Auscann's 48% Equity in Cannpal for a$2M

THOMSON REUTERS

Argent BioPharma Terminates CFO Igor Bluvstein

Argent Biopharma Ltd-Corporate Update

THOMSON REUTERS

Argent Biopharma Ltd - Transitions Financial Management to Australia

THOMSON REUTERS

Argent Biopharma Secures A$11m Financing Facility from C/M Capital for Strategic Acquisition

Argent Biopharma Announces Private Placement to Raise Capital

Argent Biopharma Ltd-Proposed Issue of Securities - RGT

THOMSON REUTERS

Argent Biopharma Ltd-a$11M Financing Facility to Complete Strategic Acquisition

THOMSON REUTERS

Argent Biopharma Ltd. Announces Date for Upcoming Annual General Meeting

BRIEF-Argent Is Growing Through M&A Projected Merged Company Value Of $100M In Ac8 Asset Acquisition

Argent Biopharma Ltd. Announces Strategic Acquisition of AusCann's Core Assets to Boost U.S. Listing Prospects

Argent Is Growing Through M&a: Projected Merged Company Value of $100M in Ac8 Asset Acquisition

THOMSON REUTERS

Press Release: Argent is Growing Through M&A: Projected Merged Company Value of $100M in AC8 Asset Acquisition

BUZZ-Australia's Argent BioPharma set for best day in a year on AusCann deal

BRIEF-Argent Biopharma To Acquire Core Operating Assets And IP Portfolio Of Auscann Group

Argent Biopharma Ltd. to Acquire AusCann Assets, Expanding Clinical Pipeline and European Presence

Argent Biopharma - Binding Term Sheet to Acquire Core Operating Assets and Ip Portfolio of Auscann Group Holdings

THOMSON REUTERS

Argent Biopharma Ltd - Will Issue Ac8 25 Mln Ordinary Shares, Valued at USD 15 Mln

THOMSON REUTERS

Argent BioPharma Says Case Study Confirms Treatment of Lennox-Gastaut Syndrome Patient with Cannabinoid-Based Formulation

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RGT.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RGT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RGT.AU\",,,,,undefined,":{"symbol":"RGT.AU","market":"AU","secType":"STK","nameCN":"Argent BioPharma Limited","latestPrice":0.057,"timestamp":1770959520000,"preClose":0.057,"halted":0,"volume":11240,"delay":0,"changeRate":0,"nameEN":"Argent BioPharma Limited","floatShares":27704074,"shares":86942317,"eps":-0.312116,"marketStatus":"Market Closed","change":0,"latestTime":"02-13 16:12:00 AEDT","open":0.057,"high":0.057,"low":0.057,"amount":641,"amplitude":0,"askPrice":0.059,"askSize":11000,"bidPrice":0.057,"bidSize":46259,"shortable":3,"etf":0,"ttmEps":-0.312116,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1771196400000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.057,"openAndCloseTimeList":[[1770937200000,1770958800000]],"volumeRatio":0.34976568232284955,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RGT.AU\",,,,,undefined,":{"symbol":"RGT.AU","floatShares":27704074,"roa":"-147.52%","roe":"--","lyrEps":-0.312116,"volumeRatio":0.34976568232284955,"shares":86942317,"dividePrice":0,"high":0.057,"amplitude":0,"preClose":0.057,"low":0.057,"week52Low":0.052,"pbRate":"-0.57","psRate":"27.45","week52High":0.32,"institutionHeld":0,"latestPrice":0.057,"committee":0.615781,"eps":-0.312116,"divideRate":0,"volume":11240,"delay":0,"ttmEps":-0.312116,"open":0.057,"prevYearClose":0.07,"prevWeekClose":0.054,"prevMonthClose":0.055,"prevQuarterClose":0.07,"fiveDayClose":0.054,"twentyDayClose":0.059,"sixtyDayClose":0.082},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RGT.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-09-23","symbol":"RGT.AU","reason":null,"defaultRemindTime":1727049600000,"announcedDate":"2024-08-15","type":"delisting","dateTimestamp":1727013600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RGT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RGT.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2603655322","title":"Argent Biopharma Ltd-Streamlined Acquisition of Auscann Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2603655322","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603655322?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:26","pubTimestamp":1768343168,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUE8CXH1V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2603553276","title":"Argent Biopharma Ltd - to Buy Auscann's 48% Equity in Cannpal for a$2M","url":"https://stock-news.laohu8.com/highlight/detail?id=2603553276","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603553276?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:26","pubTimestamp":1768343168,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUE8CXH1V:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RGT.AU"],"gpt_icon":0},{"id":"2589069288","title":"Argent BioPharma Terminates CFO Igor Bluvstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2589069288","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589069288?lang=en_us&edition=fundamental","pubTime":"2025-12-08 05:36","pubTimestamp":1765143389,"startTime":"0","endTime":"0","summary":"Argent BioPharma Ltd. has terminated the employment agreement of Mr Igor Bluvstein, who served as Chief Financial Officer, and removed him from all positions within the company's subsidiaries effective immediately. The company is restructuring its finance and reporting functions, transitioning all financial management activities from its internal team in Slovenia to an external provider in Australia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL88ts8C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RGT.AU"],"gpt_icon":0},{"id":"2589986806","title":"Argent Biopharma Ltd-Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2589986806","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589986806?lang=en_us&edition=fundamental","pubTime":"2025-12-08 05:30","pubTimestamp":1765143007,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nTUE2TYVQ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2589069828","title":"Argent Biopharma Ltd - Transitions Financial Management to Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2589069828","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589069828?lang=en_us&edition=fundamental","pubTime":"2025-12-08 05:30","pubTimestamp":1765143007,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nTUE2TYVQ1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2584699456","title":"Argent Biopharma Secures A$11m Financing Facility from C/M Capital for Strategic Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2584699456","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584699456?lang=en_us&edition=fundamental","pubTime":"2025-11-17 07:03","pubTimestamp":1763334212,"startTime":"0","endTime":"0","summary":"Argent Biopharma Ltd. has secured a new A$11 million financing facility with US-based venture fund C/M Capital to support the completion of its strategic acquisition of AusCann Group assets and to finance future growth strategies. The agreement, involving two institutional funds managed by C/M Capital Partners, LP, provides an immediate A$3 million drawdown for working capital and the acquisition. Additionally, Argent has executed a deed of variation with Mercer Street Global Fund LLC to amend the terms of existing convertible notes, subject to shareholder approval at the 2025 Annual General Meeting. This funding positions Argent to complete its acquisition, strengthen its operational and financial base, and accelerate its plans for a dual listing on a major US stock exchange.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for information","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251116:nNDLccn5L4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RGT.AU"],"gpt_icon":0},{"id":"2584994596","title":"Argent Biopharma Announces Private Placement to Raise Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584994596","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584994596?lang=en_us&edition=fundamental","pubTime":"2025-11-17 07:03","pubTimestamp":1763334205,"startTime":"0","endTime":"0","summary":"Argent Biopharma Ltd. has announced a proposed placement involving the issue of 21,950,952 unlisted options and 11,000,000 convertible notes. The placement is subject to security holder approval, with the determination set for November 28, 2025. The funds raised through this offering are intended to support the completion of the AusCann transaction and provide general working capital for operational activities. The proposed issue date for the securities is December 1, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251116:nNDL97dc8q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2584699529","title":"Argent Biopharma Ltd-Proposed Issue of Securities - RGT","url":"https://stock-news.laohu8.com/highlight/detail?id=2584699529","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584699529?lang=en_us&edition=fundamental","pubTime":"2025-11-17 06:44","pubTimestamp":1763333074,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251116:nTUE8FGLBT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2584544699","title":"Argent Biopharma Ltd-a$11M Financing Facility to Complete Strategic Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2584544699","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584544699?lang=en_us&edition=fundamental","pubTime":"2025-11-17 06:42","pubTimestamp":1763332945,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251116:nTUE4ZT0MM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RGT.AU"],"gpt_icon":0},{"id":"2579927840","title":"Argent Biopharma Ltd. Announces Date for Upcoming Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2579927840","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579927840?lang=en_us&edition=fundamental","pubTime":"2025-10-29 16:50","pubTimestamp":1761727824,"startTime":"0","endTime":"0","summary":"Argent Biopharma Ltd. will hold its Annual General Meeting on 28 November 2025 at Suite 1, 295 Rokeby Road, Subiaco, WA. Shareholders will receive and consider the company's annual financial report for the year ended 30 June 2025, including the Directors' declaration, the Directors' report, the Remuneration Report, and the auditor's report. Resolutions to be voted on during the meeting include the adoption of the Remuneration Report, the election of Director Gary Hermon, approval for the company to issue up to 10% of its issued capital under a 7.1A mandate, and the renewal of proportional takeover provisions in the company's constitution for a further three years.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. pub","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL8gsfY8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2562773298","title":"BRIEF-Argent Is Growing Through M&A Projected Merged Company Value Of $100M In Ac8 Asset Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2562773298","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562773298?lang=en_us&edition=fundamental","pubTime":"2025-08-28 05:50","pubTimestamp":1756331409,"startTime":"0","endTime":"0","summary":"BRIEF-Argent Is Growing Through M&A Projected Merged Company Value Of $100M In Ac8 Asset AcquisitionAug 27 (Reuters) - Argent BioPharma Ltd RGT.AX:ARGENT IS GROWING THROUGH M&A: PROJECTED MERGED COMPA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nTUA63JGQH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2562544773","title":"Argent Biopharma Ltd. Announces Strategic Acquisition of AusCann's Core Assets to Boost U.S. Listing Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2562544773","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562544773?lang=en_us&edition=fundamental","pubTime":"2025-08-28 05:30","pubTimestamp":1756330244,"startTime":"0","endTime":"0","summary":"Argent BioPharma Ltd has announced the signing of a binding term sheet to acquire the core assets and intellectual property of AusCann Group Holdings Ltd. This acquisition includes the Neuvis patented drug delivery platform, FDA-facing epilepsy pre-clinical data, and EU-based commercial infrastructure. The USD 15 million share-based transaction is expected to enhance Argent's lead programs, CannEpil and CimetrA, expand its European footprint, and add significant audited assets. The transaction, which is anticipated to be completed in Q3 2025, aims to strengthen Argent's clinical pipeline and intellectual property portfolio while supporting its planned dual U.S. national exchange listing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nNDL7qR0GW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2562773510","title":"Argent Is Growing Through M&a: Projected Merged Company Value of $100M in Ac8 Asset Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2562773510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562773510?lang=en_us&edition=fundamental","pubTime":"2025-08-28 05:30","pubTimestamp":1756330202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nTUA63JGQH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2562735777","title":"Press Release: Argent is Growing Through M&A: Projected Merged Company Value of $100M in AC8 Asset Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2562735777","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562735777?lang=en_us&edition=fundamental","pubTime":"2025-08-28 05:30","pubTimestamp":1756330200,"startTime":"0","endTime":"0","summary":"Acquisition Expands Clinical Pipeline, Strengthens IP Portfolio, and Grows EU Presence. Binding term sheet signed to acquire key assets and IP of AusCann Group Holdings Ltd.Assets include Neuvis drug delivery platform, FDA-facing epilepsy pre-clinical data, EU-GMP manufacturing, and German pharma distribution.Strengthens Argent's clinical pipeline, IP portfolio, and European infrastructure.Adds audited assets supporting Argent's planned dual U.S. national exchange listing.NEW YORK and SYDNEY, Aug. 27, 2025 /PRNewswire/ -- Argent BioPharma Ltd  has signed a binding term sheet to acquire the core assets and IP of AusCann Group Holdings Ltd . The acquisition includes the Neuvis patented drug delivery platform, validated FDA-facing epilepsy pre-clinical data supporting CannEpil, and EU-based commercial infrastructure.The USD 15M share-based transaction strengthens Argent's lead programs CannEpil and CimetrA, expands its European footprint, and adds significant audited assets, directly enha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4232","R","RGT.AU","BK7096"],"gpt_icon":0},{"id":"2560151510","title":"BUZZ-Australia's Argent BioPharma set for best day in a year on AusCann deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2560151510","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560151510?lang=en_us&edition=fundamental","pubTime":"2025-08-19 12:09","pubTimestamp":1755576555,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Argent BioPharma set for best day in a year on AusCann deal** Argent Biopharma RGT.AX surges as much as 272.1% to A$0.32; marks biggest intra-day pct gain since August 21, 2024** Stocks hits highest since October 24, 2024; eyes fourth straight session of gains** Drug discovery firm signs binding term sheet to acquire cannabinoid-based therapeutics co AusCann Group for $15 million** Co to secure Neuvis patented drug-delivery tech, FDA-facing epilepsy pre-clinical data, others under deal** About 1.8 mln shares traded in stock's busiest day ever** RGT last up 74.4%, trimming YTD losses to 26.5%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nL4N3UB07R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2560158610","title":"BRIEF-Argent Biopharma To Acquire Core Operating Assets And IP Portfolio Of Auscann Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2560158610","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560158610?lang=en_us&edition=fundamental","pubTime":"2025-08-19 09:36","pubTimestamp":1755567379,"startTime":"0","endTime":"0","summary":"BRIEF-Argent Biopharma To Acquire Core Operating Assets And IP Portfolio Of Auscann GroupAug 19  - Argent BioPharma Ltd RGT.AX:BINDING TERM SHEET TO ACQUIRE CORE OPERATING ASSETS AND IP PORTFOLIO OF AUSCANN GROUP HOLDINGSWILL ISSUE AC8 25 MILLION ORDINARY SHARES, VALUED AT USD 15 MILLIONFurther company coverage: RGT.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nFWN3UA0DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGT.AU"],"gpt_icon":0},{"id":"2560113468","title":"Argent Biopharma Ltd. to Acquire AusCann Assets, Expanding Clinical Pipeline and European Presence","url":"https://stock-news.laohu8.com/highlight/detail?id=2560113468","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560113468?lang=en_us&edition=fundamental","pubTime":"2025-08-19 07:46","pubTimestamp":1755560790,"startTime":"0","endTime":"0","summary":"Argent Biopharma Ltd. has announced the signing of a binding term sheet to acquire key assets and intellectual property from AusCann Group Holdings Ltd. This acquisition includes the Neuvis drug delivery platform, FDA-facing epilepsy pre-clinical data, and access to EU-GMP manufacturing along with German pharmaceutical distribution. This strategic move enhances Argent's clinical pipeline and European commercial infrastructure, aligning with plans for a dual listing on a U.S. stock exchange. The integration of these assets is set to transform Argent's clinical execution and commercial reach, bolstering its IP-driven revenue model. The transaction is expected to be completed in Q3 2025, with integration activities already in progress.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interprete","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL50dYp1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RGT.AU"],"gpt_icon":0},{"id":"2560348921","title":"Argent Biopharma - Binding Term Sheet to Acquire Core Operating Assets and Ip Portfolio of Auscann Group Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2560348921","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560348921?lang=en_us&edition=fundamental","pubTime":"2025-08-19 07:36","pubTimestamp":1755560212,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nFWN3UA0DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2560134819","title":"Argent Biopharma Ltd - Will Issue Ac8 25 Mln Ordinary Shares, Valued at USD 15 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2560134819","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560134819?lang=en_us&edition=fundamental","pubTime":"2025-08-19 07:36","pubTimestamp":1755560212,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nFWN3UA0DK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGT.AU","BK7096"],"gpt_icon":0},{"id":"2557370753","title":"Argent BioPharma Says Case Study Confirms Treatment of Lennox-Gastaut Syndrome Patient with Cannabinoid-Based Formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2557370753","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557370753?lang=en_us&edition=fundamental","pubTime":"2025-08-05 07:58","pubTimestamp":1754351936,"startTime":"0","endTime":"0","summary":"Argent BioPharma (ASX:RGT) said that a peer-reviewed case study was published in the International Journal of Clinical Medicine & Case Reports, covering the treatment of a pediatric patient with Lenno","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RGT.AU","BK4086","LII","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}]}}